Pfizer is testing three extra-small doses of its vaccine in children under 5 after two shots didn't prove quite strong enough.
Pfizer is testing three extra-small doses of its vaccine in children under 5 after two shots didn't prove quite strong enough. Initial results had been expected last month but the company laid out the latest timeline Tuesday during its discussion of quarterlyCurrently in the U.S.
, only children ages 5 or older can be vaccinated, using Pfizer’s vaccine -- leaving 18 million younger tots unprotected.. Last week, it filed with the Food and Drug Administration data it hopes will prove two of its low-dose shots work in children younger than 5. Moderna also has filed FDA applications for older kids, although the agency hasn’t ruled on them.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Pfizer hopes to submit little-kid vaccine data by early JunePfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June
続きを読む »
Pfizer hopes to submit little-kid vaccine data by early JunePfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June.
続きを読む »
Pfizer in Q1 Profit Leap of 61%BAGGING CASH: Sales of Pfizer coronavirus vaccine and treatment pushed the drugmaker past expectations in the first quarter as profit grew 61 percent.
続きを読む »
Pfizer Q1 profit, revenue soar on COVID-19 vaccine salesCOVID-19 vaccine and treatment sales helped Pfizer breeze past Wall Street’s first-quarter expectations, as the drugmaker’s profit grew 61%.
続きを読む »
Pfizer Sales Soar on Covid-19 Vaccine SalesPfizer logged $25.7 billion in sales in the first-quarter, driven by sales of vaccine Comirnaty and Paxlovid, a pill aimed at reducing severe outcomes from Covid-19
続きを読む »
Pfizer beats Q1 estimates as COVID vaccine and antiviral boost revenuePfizer Inc. undefined posted better-than-expected first-quarter earnings on Tuesday, boosted by sales of its COVID-19 vaccine and antiviral Paxlovid. The...
続きを読む »